PAR · NSE
Par Drugs And Chemicals Limited
₹164.95
-1.96% (-₹3.3)
Prev. close
₹168.25
Volume
7,26,345
Delivery %
24.9%
As of
03 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Par Drugs And Chemicals Limited
Par Drugs and Chemicals Limited develops, manufactures, and sells active pharmaceutical ingredients (APIs) and fine chemicals in India. The company provides API products, including magnesium hydroxide, magnesium oxide USP, sucralfate, almagate BP, dried aluminium hydroxide gel, light magnesium carbonate, magaldrate, magnesium trisilicate, colloidal silicon dioxide, aluminium magnesium silicate, magnesium aluminometasilicate, magnesium aluminosilicate-USP, magnesium oxide light, magnesium oxide heavy, magnesium aluminium hydrate, hydrotalcite, and synthetic aluminium silicate. It offers fine chemicals, such as precipitated silica, sodium aluminium silicate, amorphous aluminium hydroxide, Alusil, PARSIL-HT, aluminium hydroxide magnesium carbonate co-dried gel, magnesium aluminium silicate hydrated (pharma), and magnesium aluminium silicate hydrated (agro). It also exports its products. Par Drugs and Chemicals Limited was founded in 1982 and is based in Vadodara, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Jignesh Vallabhbhai Savani
Headquarters
Vadodara
Website
pardrugs.comExchange
View on NSE ↗Key stats
Market cap
₹202.96 Cr
P/E ratio (TTM)
15.5
EPS (TTM)
₹10.65
Beta (1Y · daily vs NIFTY 50)
1.28
Beta (5Y · monthly vs NIFTY 50)
1.26
Shares float
23.72 L
EPS · quarter ended Mar 2026
₹0.69
Financial Performance
01 · Financials
FY23 growth needs FY22 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based
05 · Capital Structure & Asset Utilization
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
07 · Debt Level & Coverage
08 · Profit & Loss
Annual
| Line item | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| ₹75.07 Cr | ₹95.75 Cr | ₹95.64 Cr | ₹100.97 Cr | ₹103.66 Cr | |
| EBITDA | ₹16.44 Cr | ₹18.45 Cr | ₹23.06 Cr | ₹21.65 Cr | ₹21.13 Cr |
| ₹9.22 Cr | ₹11.33 Cr | ₹14.50 Cr | ₹13.36 Cr | ₹13.11 Cr | |
| Diluted EPS | ₹7.49 | ₹9.21 | ₹11.78 | ₹10.86 | ₹10.65 |
09 · Balance Sheet
Annual
| Line item | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| ₹78.69 Cr | ₹88.87 Cr | ₹101.61 Cr | ₹119.39 Cr | ₹129.21 Cr | |
| — | ₹0 | ₹0 | ₹0 | ₹0 | |
| Stockholders' equity | ₹59.88 Cr | ₹71.24 Cr | ₹85.63 Cr | ₹98.97 Cr | ₹111.98 Cr |
Total debt, Long-term debt, Current (short-term) debt, Others have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| ₹7.62 Cr | ₹13.38 Cr | ₹20.25 Cr | ₹16.16 Cr | ₹16.43 Cr | |
| Investing cash flow | ₹-3.02 Cr | ₹-7.34 Cr | ₹-5.84 Cr | ₹-25.24 Cr | ₹-2.17 Cr |
| ₹-9.55 Cr | ₹-24,000 | ₹0 | ₹0 | ₹0 | |
| Capital expenditure | ₹-3.20 Cr | ₹-7.63 Cr | ₹-6.08 Cr | ₹-1.25 Cr | ₹-1.96 Cr |
| End cash position | ₹16.21 Cr | ₹22.24 Cr | ₹36.65 Cr | ₹27.58 Cr | ₹41.84 Cr |
Debt issued, Debt repaid, Dividends paid have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 21 | Dec 21 | Mar 22–Jun 22(2Q) | Sep 22–Jun 24(8Q) | Sep 24–Sep 25(5Q) | Dec 25–Jun 26(3Q) |
|---|---|---|---|---|---|---|
| Promoter | 73.86% | 73.98% | 74.21% | 74.21% | 73.37% | 73.41% |
| Public | 26.13% | 26.02% | 25.80% | 25.79% | 26.63% | 26.59% |
| Employee trusts | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,846.4 | 37.1 | 5.37 | 13.7% | 0.06 | +11.9% | +12.3% |
| Divi's Laboratories Limited | ₹2.48 L Cr | ₹9,624 | 84.9 | 14.81 | 15.3% | 0.00 | +12.3% | +59.0% |
| Torrent Pharmaceuticals Limited | ₹1.88 L Cr | ₹4,985 | 78.8 | 22.38 | 25.8% | 1.79 | +21.5% | +36.5% |
| Apollo Hospitals Enterprise Limited | ₹1.28 L Cr | ₹8,835.5 | 61.5 | 13.52 | 20.5% | 0.90 | +15.7% | +14.2% |
| Lenskart Solutions Limited | ₹1.20 L Cr | ₹686.7 | 181.0 | 13.70 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.16 L Cr | ₹1,170.1 | 25.9 | 4.28 | 18.6% | 0.46 | +18.4% | +12.0% |
| Cipla Limited | ₹1.12 L Cr | ₹1,384.1 | 33.2 | 3.25 | 11.3% | 0.02 | +2.1% | -10.3% |
| Laurus Labs Limited | ₹1.09 L Cr | ₹2,034 | 99.7 | 20.52 | 16.8% | 0.48 | +22.0% | +123.5% |
| Max Healthcare Institute Limited | ₹1.02 L Cr | ₹1,066.6 | 70.4 | 9.50 | 13.4% | 0.32 | +19.0% | -8.0% |
| Dr. Reddy's Laboratories Limited | ₹1.01 L Cr | ₹1,211.2 | 30.5 | 2.68 | 11.4% | 0.21 | +3.2% | -7.4% |
| Manipal Health Enterprises Limited | ₹99,126.82 Cr | ₹760.95 | 150.7 | 11.76 | 7.8% | 1.53 | +18.0% | — |
| Par Drugs And Chemicals Limited | ₹202.96 Cr | ₹164.95 | 15.5 | 1.81 | 11.7% | 0.00 | +2.7% | — |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Par Drugs and Chemicals Flags Unclaimed Dividend Shares for Transfer to IEPF
TipRanks · 1 month ago